Notice Regarding Changes to the Scheduled Spending Periods for Proceeds from the 15th Series Stock Acquisition Rights and 17th Series Stock Acquisition Rights, Both Issued by Third-Party Allotment with Exercise Price Adjustment Provisions | RIBOMIC Inc. (4591) timely disclosure

Worth reading

71In focus

Scored from 3 of 5 sections

Direction

Neutral

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Definitive

How definitive the wording is.

Details of issuance or disposal

15th Series Stock Acquisition Rights and 17th Series Stock Acquisition Rights, both issued by third-party allotment with exercise price adjustment provisions

Specific use of funds

Clinical development expenses for RBM-007 for age-related macular degeneration and achondroplasia, including drug synthesis costs for clinical developmentAmount ¥3,239 million (¥3,066 million allocated as of the end of February 2026) / Scheduled timing of expenditures January 2020 to April 2026

Nonclinical study expenses for RBM-003 for heart failureAmount ¥40 million (¥40 million allocated) / Scheduled timing of expenditures January 2020 to December 2023

Nonclinical study expenses for RBM-010 for osteoarthritisAmount ¥80 million (¥80 million allocated) / Scheduled timing of expenditures January 2020 to December 2023

New technology development expenses, including formulation technology development and licensingAmount ¥95 million (¥95 million allocated) / Scheduled timing of expenditures August 2020 to March 2024

Exploratory research expenses focused on aptamers for drug delivery systemsAmount ¥152 million (¥119 million allocated as of the end of February 2026) / Scheduled timing of expenditures June 2025 to March 2027

Working capitalAmount ¥1,880 million (¥1,530 million allocated as of the end of February 2026) / Scheduled timing of expenditures January 2020 to March 2027

Research and development expenses for RBM-006, an aptamer drug against an anti-autotaxin aptamer drugAmount ¥650 million (¥166 million allocated as of the end of February 2026) / Scheduled timing of expenditures April 2024 to March 2027

Working capitalAmount ¥44 million (－ allocated as of the end of February 2026) / Scheduled timing of expenditures April 2025 to March 2027

Terms of the stock acquisition rights

Exercise price

The rights are stated to include an exercise price adjustment provision, but the initial exercise price and adjustment floor are Not disclosed

Most recent equity financing

Timing 10 January 2020 / Type 15th Series Stock Acquisition Rights issued by third-party allotment with exercise price adjustment provisions / Amount Not disclosed, Timing 20 February 2024 / Type 17th Series Stock Acquisition Rights issued by third-party allotment with exercise price adjustment provisions / Amount Not disclosed

Impact on Business Performance

This transaction will have no impact on results for the fiscal year ending March 2026.

Details of issuance or disposal
Item	Details
Type of issuance or disposal	15th Series Stock Acquisition Rights and 17th Series Stock Acquisition Rights, both issued by third-party allotment with exercise price adjustment provisions
Specific use of funds	Details Clinical development expenses for RBM-007 for age-related macular degeneration and achondroplasia, including drug synthesis costs for clinical development / Amount ¥3,239 million (¥3,066 million allocated as of the end of February 2026) / Scheduled timing of expenditures January 2020 to April 2026, Details Nonclinical study expenses for RBM-003 for heart failure / Amount ¥40 million (¥40 million allocated) / Scheduled timing of expenditures January 2020 to December 2023, Details Nonclinical study expenses for RBM-010 for osteoarthritis / Amount ¥80 million (¥80 million allocated) / Scheduled timing of expenditures January 2020 to December 2023, Details New technology development expenses, including formulation technology development and licensing / Amount ¥95 million (¥95 million allocated) / Scheduled timing of expenditures August 2020 to March 2024, Details Exploratory research expenses focused on aptamers for drug delivery systems / Amount ¥152 million (¥119 million allocated as of the end of February 2026) / Scheduled timing of expenditures June 2025 to March 2027, Details Working capital / Amount ¥1,880 million (¥1,530 million allocated as of the end of February 2026) / Scheduled timing of expenditures January 2020 to March 2027, Details Research and development expenses for RBM-006, an aptamer drug against an anti-autotaxin aptamer drug / Amount ¥650 million (¥166 million allocated as of the end of February 2026) / Scheduled timing of expenditures April 2024 to March 2027, Details Working capital / Amount ¥44 million (－ allocated as of the end of February 2026) / Scheduled timing of expenditures April 2025 to March 2027
Exercise price	The rights are stated to include an exercise price adjustment provision, but the initial exercise price and adjustment floor are Not disclosed
Most recent equity financing	Timing 10 January 2020 / Type 15th Series Stock Acquisition Rights issued by third-party allotment with exercise price adjustment provisions / Amount Not disclosed, Timing 20 February 2024 / Type 17th Series Stock Acquisition Rights issued by third-party allotment with exercise price adjustment provisions / Amount Not disclosed
Impact on Business Performance	This transaction will have no impact on results for the fiscal year ending March 2026.

Items this document does not state (23)

Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For the 15th Series Stock Acquisition Rights, the remaining funds will be allocated to a long-term administration study included in the Phase 2 clinical trial for achondroplasia. For the 17th Series Stock Acquisition Rights, the company plans to transition to CMC development and toxicity studies in anticipation of future clinical trials, based on its research findings, and made the change after considering the progress of the overall development program.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.